Skip to main content
. 2023 Jun 9;11(6):e006381. doi: 10.1136/jitc-2022-006381

Figure 1.

Figure 1

ADT and ZA plus Tα1 improve therapeutic outcomes in patients with advanced or metastatic PCa. (A) The changes in tumor growth in patients with advanced or metastatic PCa receiving ADT combined with ZA and Tα1 was determined by MRI. Representative MRI images are shown, and the red circles indicate the tumor regions in the patients with PCa. (B) Quantification of the relative area of tumors from patients with PCa pretreatment and post-treatment with ADT and ZA plus Tα1. (C) ELISA analysis of the serum levels of PSA and PAP in patients with PCa during the period of ADT and ZA plus Tα1. (D–F) ELISA analysis of the serum levels of PSA, PAP, and free PSA in patients with PCa before and after treatment with ADT and ZA plus Tα1. **P<0.01. ADT, androgen deprivation therapy; PAP, prostatic acid phosphatase; PCa, prostate cancer; PSA, prostate-specific antigen; Tα1, thymosin α1; ZA, zoledronic acid.